Pre-clinical intravenous serum pharmacokinetics of albumin binding and non-half-life extended nanobodies®

Antibodies

Volumn 4, Issue 3, 2015, Pages 141-156

  Hoefman, Sven ^a   Ottevaere, Ingrid ^a   Baumeister, Judith ^a   Sargentini Maier, Maria Laura ^a  

^a ABLYNX NV   (Belgium)

Author keywords

Albumin; Half life extension; Nanobodies; Pharmacokinetics; Pre clinical

Indexed keywords

HLE1 NANOBODY; IRR1 HLE1 NANOBODY; IRR1 IRR1 NANOBODY; IRR1 NANOBODY; IRR2 HLE2 IRR2 NANOBODY; IRR3 HLE2 NANOBODY; IRR3 NANOBODY; NANOBODY; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CENTRAL VOLUME OF DISTRIBUTION; DISSOCIATION CONSTANT; DRUG CLEARANCE; DRUG PROTEIN BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; HALF LIFE EXTENSION; HALF LIFE TIME; LIMIT OF QUANTITATION; MACACA FASCICULARIS; METABOLIC PARAMETERS; NONHUMAN; PERIPHERAL VOLUME OF DISTRIBUTION; PRIORITY JOURNAL; RABBIT; VOLUME OF DISTRIBUTION AT STEADY-STATE;

EID: 85108690991     PISSN: 20734468     EISSN: None     Source Type: Journal    
DOI: 10.3390/antib4030141     Document Type: Article

References (47)

1. Hamers-Casterman, C.; Atarhouch, T.; Muyldermans, S.; Robinson, G.; Hamers, C.; Songa, E.B.; Bendahman, N.; Hamers, R. Naturally occurring antibodies devoid of light chains. Nature 1993, 363, 446-448.
2. Harmsen, M.M.; De Haard, H.J. Properties, production, and applications of camelid single-domain antibody fragments. Appl. Microbiol. Biotechnol. 2007, 77, 13-22.
3. Muyldermans, S. Nanobodies: Natural single-domain antibodies. Ann. Rev. Biochem. 2013, 82, 775-797.
4. Van Bockstaele, F.; Holz, J.-B.; Revets, H. The development of nanobodies for therapeutic applications. Curr. Opin. Investig. Drugs 2009, 10, 1212-1224.
5. Hassanzadeh-Ghassabeh, G.; Devoogdt, N.; De Pauw, P.; Vincke, C.; Muyldermans, S. Nanobodies and their potential applications. Nanomedicine 2013, 8, 1013-1026.
6. Venkatachalam, M.A.; Rennke, H.G. The structural and molecular basis of glomerular filtration. Circul. Res. 1978, 43, 337-347.
7. Lin, J.H. Pharmacokinetics of biotech drugs: peptides, proteins and monoclonal antibodies. Curr. Drug Metab. 2009, 10, 661-691.
8. Rennke, H.G.; Patel, Y.; Venkatachalam, M.A. Glomerular filtration of proteins: Clearance of anionic, neutral, and cationic horseradish peroxidase in the rat. Kidney Int. 1978, 13, 278-288.
9. Peters, T., Jr. Serum albumin. Adv. Protein Chem. 1985, 37, 161-245.
10. Tojo, A.; Endou, H. Intrarenal handling of proteins in rats using fractional micropuncture technique. Am. J. Physiol. 1992, 263, F601-606.
11. Tojo, A.; Kinugasa, S. Mechanisms of glomerular albumin filtration and tubular reabsorption. Int. J. Nephrol. 2012, 2012, Article ID 481520.
12. Ohlson, M.; Sorensson, J.; Haraldsson, B. Glomerular size and charge selectivity in the rat as revealed by FITC-ficoll and albumin. Am. J. Physiol. 2000, 279, F84-F91.
13. Kuwabara, T.; Ishikawa, Y.; Kobayashi, H.; Kobayashi, S.; Sugiyama, Y. Renal clearance of a recombinant granulocyte colony-stimulating factor, nartograstim, in rats. Pharm. Res. 1995, 12, 1466-1469.
14. Yang, B.B.; Lum, P.K.; Hayashi, M.M.; Roskos, L.K. Polyethylene glycol modification of filgrastim results in decreased renal clearance of the protein in rats. J. Pharm. Sci. 2004, 93, 1367-1373.
15. Kuo, T.T.; Baker, K.; Yoshida, M.; Qiao, S.W.; Aveson, V.G.; Lencer, W.I.; Blumberg, R.S. Neonatal Fc receptor: From immunity to therapeutics. J. Clin. Immunol. 2010, 30, 777-789.
16. Andersen, J.T.; Sandlie, I. The versatile MHC class I-related FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics. Drug Metab. Pharmacok. 2009, 24, 318-332.
17. Sand, K.M.; Bern, M.; Nilsen, J.; Noordzij, H.T.; Sandlie, I.; Andersen, J.T. Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics. Front. Immunol. 2014, 5, 682.
18. Berson, S.A.; Yalow, R.S.; Schreiber, S.S.; Post, J. Tracer experiments with I131 labeled human serum albumin: distribution and degradation studies. J. Clin. Invest. 1953, 32, 746-768.
19. Morell, A.; Terry, W.D.; Waldmann, T.A. Metabolic properties of IgG subclasses in man. J. Clin. Invest. 1970, 49, 673-680.
20. Duttaroy, A.; Kanakaraj, P.; Osborn, B.L.; Schneider, H.; Pickeral, O.K.; Chen, C.; Zhang, G.; Kaithamana, S.; Singh, M.; Schulingkamp, R.; et al. Development of a long-acting insulin analog using albumin fusion technology. Diabetes 2005, 54, 251-258.
21. Jazayeri, J.A.; Carroll, G.J. Fc-based cytokines: Prospects for engineering superior therapeutics. BioDrugs 2008, 22, 11-26.
22. Bailon, P.; Won, C.Y. PEG-modified biopharmaceuticals. Exp. Opin. Drug Deliv. 2009, 6, 1-16.
23. Andersen, J.T.; Pehrson, R.; Tolmachev, V.; Daba, M.B.; Abrahmsen, L.; Ekblad, C. Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain. J. Biol. Chem. 2011, 286, 5234-5241.
24. Holt, L.J.; Basran, A.; Jones, K.; Chorlton, J.; Jespers, L.S.; Brewis, N.D.; Tomlinson, I.M. Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. Protein Eng. Des. Sel. 2008, 21, 283-288.
25. Muller, M.R.; Saunders, K.; Grace, C.; Jin, M.; Piche-Nicholas, N.; Steven, J.; O'Dwyer, R.; Wu, L.; Khetemenee, L.; Vugmeyster, Y.; et al. Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain. mAbs 2012, 4, 673-685.
26. Tijink, B.M.; Laeremans, T.; Budde, M.; Stigter-van Walsum, M.; Dreier, T.; de Haard, H.J.; Leemans, C.R.; van Dongen, G.A. Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: Taking advantage of modular Nanobody technology. Mol. Cancer Therap. 2008, 7, 2288-2297.
27. Carter, D.C.; Ho, J.X. Structure of serum albumin. Adv. Protein Chem. 1994, 45, 153-203.
28. Ulrichts, H.; Silence, K.; Schoolmeester, A.; de Jaegere, P.; Rossenu, S.; Roodt, J.; Priem, S.; Lauwereys, M.; Casteels, P.; Van Bockstaele, F.; et al. Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood 2011, 118, 757-765.
29. Vosjan, M.J.; Perk, L.R.; Roovers, R.C.; Visser, G.W.; Stigter-van Walsum, M.; van Bergen En Henegouwen, P.M.; van Dongen, G.A. Facile labelling of an anti-epidermal growth factor receptor Nanobody with 68Ga via a novel bifunctional desferal chelate for immuno-PET. Eur. J. Nucl. Med. Mol. Imag. 2011, 38, 753-763.
30. Gainkam, L.O.; Huang, L.; Caveliers, V.; Keyaerts, M.; Hernot, S.; Vaneycken, I.; Vanhove, C.; Revets, H.; De Baetselier, P.; Lahoutte, T. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J. Nucl. Med. 2008, 49, 788-795.
31. Davies, B.; Morris, T. Physiological Parameters in Laboratory Animals and Humans. Pharm. Res. 1993, 10, 1093-1096.
32. Lote, C. Principles of Renal Physiology, 5th ed.; Springer: New York, NY, USA, 2012.
33. Lenting, P.J.; Westein, E.; Terraube, V.; Ribba, A.S.; Huizinga, E.G.; Meyer, D.; de Groot, P.G.; Denis, C.V. An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation. J. Biol. Chem. 2004, 279, 12102-12109.
34. Sarav, M.; Wang, Y.; Hack, B.K.; Chang, A.; Jensen, M.; Bao, L.; Quigg, R.J. Renal FcRn reclaims albumin but facilitates elimination of IgG. J. Am. Soc. Nephrol. 2009, 20, 1941-1952.
35. Kim, J.; Bronson, C.L.; Hayton, W.L.; Radmacher, M.D.; Roopenian, D.C.; Robinson, J.M.; Anderson, C.L. Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces. Am. J. Physiol. 2006, 290, G352-G360.
36. Borvak, J.; Richardson, J.; Medesan, C.; Antohe, F.; Radu, C.; Simionescu, M.; Ghetie, V.; Ward, E.S. Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice. Int. Immunol. 1998, 10, 1289-1298.
37. Nguyen, A.; Reyes, A.E., 2nd; Zhang, M.; McDonald, P.; Wong, W.L.; Damico, L.A.; Dennis, M.S. The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin. Protein Eng. Des. Sel. 2006, 19, 291-297.
38. Lobo, E.D.; Hansen, R.J.; Balthasar, J.P. Antibody pharmacokinetics and pharmacodynamics. J. Pharm. Sci. 2004, 93, 2645-2668.
39. Deng, R.; Iyer, S.; Theil, F.P.; Mortensen, D.L.; Fielder, P.J.; Prabhu, S. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: What have we learned? mAbs 2011, 3, 61-66.
40. Petkova, S.B.; Akilesh, S.; Sproule, T.J.; Christianson, G.J.; Al Khabbaz, H.; Brown, A.C.; Presta, L.G.; Meng, Y.G.; Roopenian, D.C. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int. Immunol. 2006, 18, 1759-1769.
41. Vugmeyster, Y.; Szklut, P.; Tchistiakova, L.; Abraham, W.; Kasaian, M.; Xu, X. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms. Int. Immunopharm. 2008, 8, 477-483.
42. Lin, Y.S.; Nguyen, C.; Mendoza, J.L.; Escandon, E.; Fei, D.; Meng, Y.G.; Modi, N.B. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J. Pharm. Exp. Therap. 1999, 288, 371-378.
43. Ober, R.J.; Radu, C.G.; Ghetie, V.; Ward, E.S. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int. Immunol. 2001, 13, 1551-1559.
44. Holz, J.B. The TITAN trial--assessing the efficacy and safety of an anti-von Willebrand factor Nanobody in patients with acquired thrombotic thrombocytopenic purpura. Transf. Apheresis Sci. 2012, 46, 343-346.
45. De Bruyn, S.; De Smedt, T.; Allosery, K.; Crabbe, P.; De Brabandere, V.; Detalle, L.; Mortier, K.; Schoolmeester, A.; Wouters, A.; Stöhr, T.; et al. ALX-0171: Safety and Therapeutic Potential of an Inhaled Anti-RSV Nanobody. Respirat. Drug Deliv. Eur. 2015, in press.
46. Holz, J.B.; Sargentini-Maier, L.; De Bruyn, S.; Gachályi, B.; Udvaros, I.; Rojkovich, B.; Bruk, S.; Sramek, P.; Korkosz, M.; Krause, K.; et al. Twenty-four weeks of treatment with a novel anti-IL6 receptor nanobody (ALX-0061) resulted in 84% ACR20 improvement and 58% DAS28 remission in a phase I/II study in RA. Ann. Rheumat. Dis. 2013, 72, 64.
47. Arbabi Ghahroudi, M.; Desmyter, A.; Wyns, L.; Hamers, R.; Muyldermans, S. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett. 1997, 414, 521-526.